专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US11959919B2 Predicting cancer progression 有权
公开(公告)号：US11959919B2
公开(公告)日：2024-04-16
申请号：US16730778
申请日：2019-12-30
申请人： AROCELL AB
发明人： Sven Skog , Staffan Eriksson , Bernard Tribukait , Qimin He
IPC分类号： G01N33/574
CPC分类号： G01N33/57488 , G01N2333/91215 , G01N2800/54
摘要： Method of selecting treatment for a subject diagnosed with cancer comprises contacting antibody that binds specifically to thymidine kinase 1 (TK1) protein with a first body fluid sample before completing cancer treatment; determining a first amount of antibody binding to TK1 protein in the first sample; correlating the first amount to a first concentration of TK1 protein using a standard curve correlating an amount of antibody binding to recombinant human TK1 (rhTK1) and a concentration of rhTK1; contacting the antibody with a second body fluid sample within one to six months after the cancer treatment; determining a second amount of antibody binding to TK1 protein in the second sample; correlating the second amount to a second concentration using the curve; identifying the patient as having a high risk of future cancer relapse if the second concentration is ≥ the first concentration; and selecting an adjuvant treatment based on the identification.

2. 发明申请

US20190002587A1 MONOCLONAL ANTI-TK1 ANTIBODIES 审中-公开
公开(公告)号：US20190002587A1
公开(公告)日：2019-01-03
申请号：US16132047
申请日：2018-09-14
申请人： AROCELL AB
发明人： Staffan ERIKSSON
IPC分类号： C07K16/40 , G01N33/573 , C12N9/12
摘要： The embodiments relate to monoclonal antibodies or fragments capable of binding to a serum form of human TK1 and to kits and methods involving the use of such monoclonal antibodies or fragments.

3. 发明授权

US10100128B2 Monoclonal anti-TK1 antibodies 有权
公开(公告)号：US10100128B2
公开(公告)日：2018-10-16
申请号：US15105999
申请日：2014-12-18
申请人： AROCELL AB
发明人： Staffan Eriksson
IPC分类号： C07K16/40 , C12N9/12 , G01N33/573
摘要： Monoclonal antibodies and fragments thereof are capable of binding to a serum form of human TK1. Kits and methods involve the use of such monoclonal antibodies or fragments.

4. 发明申请

US20160311927A1 MONOCLONAL ANTI-TK1 ANTIBODIES 审中-公开
标题翻译：单克隆抗体TK1抗体
公开(公告)号：US20160311927A1
公开(公告)日：2016-10-27
申请号：US15105999
申请日：2014-12-18
申请人： AROCELL AB
发明人： Staffan Eriksson
IPC分类号： C07K16/40 , G01N33/573 , C12N9/12
CPC分类号： C07K16/40 , C07K2317/34 , C12N9/1211 , C12Y207/01021 , G01N33/573 , G01N2333/9122 , G01N2800/26 , G01N2800/54 , G01N2800/7023
摘要： The embodiments relate to monoclonal antibodies or fragments capable of binding to a serum form of human TK1 and to kits and methods involving the use of such monoclonal antibodies or fragments.
摘要翻译：实施方案涉及能够结合血清形式的人TK1的单克隆抗体或片段以及涉及使用这种单克隆抗体或片段的试剂盒和方法。

5. 发明申请

US20220221456A1 RESPIRATORY INFECTION DETECTION AND CLASSIFICATION 有权
公开(公告)号：US20220221456A1
公开(公告)日：2022-07-14
申请号：US17608255
申请日：2020-05-05
申请人： AROCELL AB
发明人： Staffan ERIKSSON , Per VENGE
IPC分类号： G01N33/569 , G01N33/573 , C07K16/40
摘要： The present invention relates to diagnosing and classifying respiratory infections based on determined TK1 protein levels in body samples. In particular, a respiratory infection can be diagnosed and classified as Mycoplasma pneumonia caused by Mycoplasma pneumoniae based on the determined TK1 protein level.

6. 发明授权

US10551385B2 Predicting cancer progression 有权
公开(公告)号：US10551385B2
公开(公告)日：2020-02-04
申请号：US15357762
申请日：2016-11-21
申请人： AROCELL AB
发明人： Sven Skog , Staffan Eriksson , Bernard Tribukait , Qimin He
IPC分类号： G01N33/574
摘要： Method of determining a likelihood of cancer relapse in a subject who has completed cancer tumor surgery, radiotherapy treatment and/or chemotherapy treatment comprises contacting an antibody that binds specifically to a serum form of thymidine kinase 1 (STK1) protein with a blood serum sample one to six months after completing the surgery and/or treatment, and before any cancer relapse has been detected; determining an amount of antibody binding to STK1 protein in the sample; correlating the amount of antibody binding to STK1 protein to a concentration of STK1 protein in the sample; and based on the concentration of STK1 protein in the sample, generating decision support information representative of a likelihood of cancer relapse in the subject one to ten years after completion of the surgery and/or treatment, the decision support information comprising a likelihood value defining one of a high or low likelihood of cancer relapse.

7. 发明公开

US20240288432A1 PREDICTING CANCER RELAPSE 审中-公开
公开(公告)号：US20240288432A1
公开(公告)日：2024-08-29
申请号：US18572370
申请日：2022-06-21
申请人： AROCELL AB
发明人： Staffan ERIKSSON , Per VENGE
IPC分类号： G01N33/574 , C07K16/40
CPC分类号： G01N33/57426 , C07K16/40 , C07K2317/34 , C07K2317/565 , G01N2333/9122 , G01N2800/54
摘要： The invention relates to predicting cancer relapse or predicting patient survival by determining a level of serum thymidine kinase 1 (STK1) material in a body sample from a patient diagnosed with hematological cancer using an antibody or a fragment thereof specifically binding to a serum form of human TK1. The determined level of STK1 material is compared with a threshold value selected based on an age of the patient. Cancer relapse is then predicted based on the comparison.

8. 发明申请

US20230070840A1 PREDICTING PATIENT SURVIVAL 有权
公开(公告)号：US20230070840A1
公开(公告)日：2023-03-09
申请号：US17794286
申请日：2021-01-29
申请人： AROCELL AB
发明人： Staffan ERIKSSON , Martin SHAW , Teuvo TAMMELA , Teemu MURTOLA
IPC分类号： G01N33/574 , G01N33/543
摘要： A method for predicting patient survival comprises determining a level of STK1 (serum thymidine kinase 1) material in a body sample from a patient diagnosed with prostate cancer using an antibody or a fragment thereof specifically binding to a serum form of human TK1. The method also comprises predicting survival of the patient based on the determined level of STK1 material in the body sample.

9. 发明申请

US20170067900A1 PREDICTING CANCER PROGRESSION 审中-公开
标题翻译：预测癌症进展
公开(公告)号：US20170067900A1
公开(公告)日：2017-03-09
申请号：US15357762
申请日：2016-11-21
申请人： AROCELL AB
发明人： Sven SKOG , Staffan ERIKSSON , Bernard TRIBUKAIT , Qimin HE
IPC分类号： G01N33/574
CPC分类号： G01N33/57488 , G01N2333/91215 , G01N2800/54
摘要： Method of determining a likelihood of cancer relapse in a subject who has completed cancer tumor surgery, radiotherapy treatment and/or chemotherapy treatment comprises contacting an antibody that binds specifically to a serum form of thymidine kinase 1 (STK1) protein with a blood serum sample one to six months after completing the surgery and/or treatment, and before any cancer relapse has been detected; determining an amount of antibody binding to STK1 protein in the sample; correlating the amount of antibody binding to STK1 protein to a concentration of STK1 protein in the sample; and based on the concentration of STK1 protein in the sample, generating decision support information representative of a likelihood of cancer relapse in the subject one to ten years after completion of the surgery and/or treatment, the decision support information comprising a likelihood value defining one of a high or low likelihood of cancer relapse.
摘要翻译：确定完成癌肿瘤手术，放射治疗和/或化学疗法治疗的受试者中癌症复发的可能性的方法包括将与血清形式的胸苷激酶1（STK1）蛋白特异性结合的抗体与血清样品一在完成手术和/或治疗后6个月，并且在检测到任何癌症复发之前; 测定样品中与STK1蛋白结合的抗体量; 将抗体与STK1蛋白的结合量与样品中STK1蛋白的浓度相关联; 并且基于样品中STK1蛋白的浓度，产生代表手术和/或治疗完成后1至10年在受试者中癌症复发的可能性的决策支持信息，所述决策支持信息包括定义一个的似然值癌症复发的可能性很高或很低。

10. 发明申请

WO2008142664A3 EXPOSED THYMIDINE KINASE 1 PEPTIDES, LIGANDS AND METHODS EMPLOYING THE SAME 审中-公开
标题翻译：暴露的噻霉素激酶1肽，配体及其使用方法
公开(公告)号：WO2008142664A3
公开(公告)日：2009-05-14
申请号：PCT/IB2008052051
申请日：2008-05-23
申请人： AROCELL AB , ERIKSSON STAFFAN
发明人： ERIKSSON STAFFAN
IPC分类号： C12N9/12
CPC分类号： C12N9/1211
摘要： Novel thymidine kinase (TK1) derived peptide consisting of the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2 is employed to obtain ligands having specificity to the peptide. The ligand may be an antibody or fragment thereof and may be used in various methods and kits for health screening and the like.
摘要翻译：使用由SEQ ID NO：1或SEQ ID NO：2的氨基酸序列组成的新型胸苷激酶（TK1）衍生肽获得对肽具有特异性的配体。配体可以是抗体或其片段，并且可以用于各种用于健康检查等的方法和试剂盒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式